Seeking Alpha

QualityStocks'  Instablog

QualityStocks
Send Message
QualityStocks (www.qualitystocks.net) assists publicly traded companies by getting their story out to the investment community while helping investors discover emerging companies with plenty of growth potential. Our name, QualityStocks, emphasizes our commitment to connect subscribers with... More
My company:
QualityStocks
My blog:
QualityStocks Micro-Cap and Small-Cap Blog
  • International Stem Cell Corp. (ISCO) Recognized With Prestigious Award By The American Association For The Study Of Liver Disease 0 comments
    Dec 18, 2013 11:01 AM | about stocks: ISCO

    California biotechnology company International Stem Cell Corp. has announced that the American Association for the Study of Liver Disease (AASLD) awarded the company with its Presidential Poster of Distinction at the 64th Annual Liver Meeting in Washington, D.C.

    "Being awarded such a prestigious honor is a testament to the quality of our scientific team," said Ruslan Semechkin, Ph.D., ISCO's Chief Scientific Officer. "The data presented at this conference demonstrates the unique nature of our hepatocytes cells (HLCs) and their potential efficacy in a clinical setting."

    ISCO focuses on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research. The AASLD recognized a pre-clinical study whose data demonstrated that transplantation of hpSC-derived HLCs elicits a significant decrease and long-term stabilization of bilirubin levels in the serum of Gunn rats. Moreover, at four months following treatment, no adverse safety signals were detected.

    Gunn rats are a well-established animal model of Crigler-Najjar syndrome type 1 (CN1), an inborn error of bilirubin metabolism. CN1 is a rare inherited liver-based metabolic disorder in which the host liver lacks one hepatic enzyme, UGT1A1, which is essential for the conjugation and excretion of the toxin bilirubin.

    ISCO's pre-clinical study provides evidence that supports the potential safety and efficacy of HLCs which could constitute a reliable source for large numbers of transplantable cells. In the long-term, experience with HLC transplantation for CN1 could potentially be used to develop therapeutic strategies for more common inherited liver diseases.

    Interested parties can access more information about the company at its website, internationalstemcell.com

    QualityStocks provides investor relations services to publicly traded companies in exchange for compensation. This article may be part of our efforts to widen a client's exposure. To read our full disclaimer, visit http://disclaimer.qualitystocks.net

    Stocks: ISCO
Back To QualityStocks' Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers

StockTalks

More »
Posts by Themes
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.